Medical Staff News
-
Caresyntax Announces Highlights of 2023
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
By Caresyntax
-
5 Challenges Facing UK Healthcare Organisations in 2024
As we look into the new year, the healthcare landscape in the UK is undergoing a number of changes. From digital transformation to evolving regulations, healthcare organisations across the UK are facing a number of challenges in 2024. We delve into five potential challenges confronting healthcare providers across the UK to help them prepare for the year ahead. ...
-
Caresyntax Announces Launch of Novel Real World Evidence (RWE) Program and Software Portfolio of Digital Catalysts for Commercial Acceleration of Medtech Partners
Caresyntax, the leading vendor-neutral surgical data and intelligence platform converging AI-powered software, devices, and clinical services, today announced the launch of Caresyntax Clinical Data as a Service (CDaaS) for Medtech industry partners. The launch of Caresyntax CDaaS follows the recently announced addition of CQInsights (CQI) and appointment of Dr. Bruce Ramshaw as Chief Medical ...
By Caresyntax
-
Synaptive Medical Announces Timothy J. Scannell as New Chair of Board of Directors
Synaptive Medical, a global medical device and technology company solving surgical, imaging and data challenges, is pleased to announce the appointment of Timothy J. Scannell as the new Chair of the Board of Directors, effective June 20, 2023. Mr. Scannell joined Synaptive Medical’s Board of Directors in August 2022, bringing a wealth of experience and expertise in the medical device ...
-
The best laser hair removal machine brand
Laser hair removal targets the melanin in the hair follicle and the laser destroys the pigment thereby destroying the entire hair follicle. Laser hair removal is influenced by a number of factors such as the area of hair, skin and hair colour, the stage of growth the hair, the types of laser hair removal machine and the schedule of treatment. If you choose laser hair removal machine treatment, it ...
-
More than muscles: Sports nutrition evolves
Ingredients for muscle mass and post-workout recovery remain mainstays in sports nutrition, but the category is evolving and broadening. Ingredient examples are phospholipids for cognition and probiotic cultures for digestive health. “It’s very well-known that health is increasingly perceived holistically by consumers, especially younger demographics,” said Paige Wilkinson, ...
By Nuritas Ltd.
-
Forbes: Why Big Food Is Looking to AI to Shape the Future of Food
This week, French dairy giant Bel Group announced they had entered into a partnership with Climax Foods, an AI-driven food startup founded by former Google head of data science and astrophysicist Oliver Zahn. The collaboration seeks to harness the power of artificial intelligence to develop plant-based alternatives to traditional dairy products that offer the same taste, mouthfeel, and ...
By Nuritas Ltd.
-
The Importance of Optimal Medical Therapy (OMT) and Collaborative Care
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
-
Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
By Bayer AG
-
Ony Biotech Prepares For The Future
Dr. James Cummings has been an unofficial member of the ONY Biotech family since 1989, when he first started working at the Children’s Hospital of Buffalo. This month, it becomes official, as Dr. Cummings joins the ONY Biotech team as Chief Medical Officer, and the founder of the company and former Chief Medical Officer, Dr. Edmund Egan, steps into the role of Chief Scientific Officer. ...
By ONY Biotech
-
Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has recently closed an ...
-
Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer’s Disease (CTAD) Conference and Society for Neuroscience Meeting
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at the Society for ...
-
Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
Cellworks Group Inc., a leader in Personalized Therapy Biosimulation, today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation. The two new business units will use Cellworks’ biosimulation platform and ...
-
Testing Your Bone Density for Osteoporosis Awareness Month
Testing your bone density may not be a usual task on your priority list, but May serves as National Osteoporosis Month and can serve as a friendly reminder to check your bone density. Osteoporosis is a skeletal condition that affects far more women than it does men. Low bone mass puts you more at risk for osteoporosis, so regular and early bone density testing can greatly help you. Beam Med is a ...
By BeamMed Inc.
-
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA (pembrolizumab)
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started enrolling patients in Q2 2022 and will ...
-
Galapagos announces changes to Executive Committee
Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Officer and member of the Executive Committee. Dr. Paul ...
By Galapagos NV
-
Iterative Health Partners with Gastro Health to Accelerate Clinical Research in Gastroenterology Through Artificial Intelligence
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. This strategic partnership will lay the groundwork for future collaborations by using AIR to aid ...
-
Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. In this preclinical study: continuous delivery of lenalidomide resulted in improvements in the ...
-
ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
-
XF-73 Nasal Phase 3 development plans finalised
Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal. Highlights Discussions held ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you